- Guardant Health ( NASDAQ: GH ) announced Wednesday that UnitedHealthcare, the insurance arm of UnitedHealth Group ( UNH ), has decided to cover the company’s Guardant360 CDx liquid biopsy test for all its commercial policies.
- The new coverage decision allows reimbursement for Guardant360 CDx from UnitedHealthcare when used for all FDA-approved companion diagnostic indications, i.e., in non-small cell lung cancer (NSCLC) and advanced breast cancer.
- This adds to UnitedHealthcare’s existing coverage of the Guardant360 CDx test for its Medicare Advantage policies for comprehensive genomic profiling of all solid tumors.
- “The biomarker identification available through the Guardant360 CDx blood test can enable oncologists to quickly identify patients who may benefit from a therapy targeted to their specific type of mutation to help improve their outcomes,” Guardant’s ( GH ) co- CEO Helmy Eltoukhy said .
- Seeking Alpha contributor BioSci Capital Partners recently reiterated the Buy rating on Guardant ( GH ), citing the latest data for a blood cancer test the company designed to detect colorectal cancer.
For further details see:
Guardant wins UnitedHealthcare coverage for cancer diagnostic test